<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159042</url>
  </required_header>
  <id_info>
    <org_study_id>302803-HMO-CTIL</org_study_id>
    <nct_id>NCT00159042</nct_id>
  </id_info>
  <brief_title>Genetic Factors Affecting the Severity of Beta Thalassemia</brief_title>
  <official_title>Identification of Novel Genetic Modifiers in Beta-thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with genetic diseases can have widely differing severities. We are looking for
      genetic factors which influence the severity of beta thalassemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The understanding of the phenotypic variability of genetically homogeneous disorders
      represents a major challenge. In beta thalassemia, the beta globin gene is affected by a
      variety of mutations. The group of patients to be analyzed here is homozygous for a splice
      site mutation that is common in the Middle East. In contrast to this genetic homogeneity,
      the spectrum of the clinical phenotype ranges from mild anemia to most severe, transfusion
      dependent anemia. We will use a genetic linkage approach to identify modifying factors and
      by analyzing the efficiency of an mRNA surveillance mechanism that is referred to as
      nonsense-mediated decay and represents a candidate genetic modifier of beta thalassemia and
      other genetic disorders.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Beta Thalassemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA isolated from peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients analyzed for beta thalassemia in our laboratory in Hadassah.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Identification of homozygous IVS1 nt 6 beta thalassemia mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariella Oppenheim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Rund, MD</last_name>
    <phone>00 972 2 6778712</phone>
    <email>rund@cc.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>IL91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Ariella Oppenheim, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Rund, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dvora Filon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Rund D, Oron-Karni V, Filon D, Goldfarb A, Rachmilewitz E, Oppenheim A. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol. 1997 Jan;54(1):16-22.</citation>
    <PMID>8980256</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 22, 2011</lastchanged_date>
  <firstreceived_date>September 9, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Deborah Rund</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
